// API callback
jQuery1113049251757375895977_1472024019891({"version":"1.0","encoding":"UTF-8","feed":{"xmlns":"http://www.w3.org/2005/Atom","xmlns$openSearch":"http://a9.com/-/spec/opensearchrss/1.0/","xmlns$blogger":"http://schemas.google.com/blogger/2008","xmlns$georss":"http://www.georss.org/georss","xmlns$gd":"http://schemas.google.com/g/2005","xmlns$thr":"http://purl.org/syndication/thread/1.0","id":{"$t":"tag:blogger.com,1999:blog-1574330275867774277"},"updated":{"$t":"2016-08-22T09:14:39.667+10:00"},"category":[{"term":"Australia"},{"term":"Patentable subject matter"},{"term":"News"},{"term":"Law reform"},{"term":"US"},{"term":"Patent Office"},{"term":"Computer programs"},{"term":"Patent law"},{"term":"Apple-v-Samsung"},{"term":"Genetic technology"},{"term":"Appeal"},{"term":"Smartphone wars"},{"term":"Infringement"},{"term":"Innovation policy"},{"term":"Pharmaceuticals"},{"term":"Business processes"},{"term":"New Zealand"},{"term":"Raising the Bar"},{"term":"Public policy"},{"term":"Interlocutory injunction"},{"term":"Obviousness"},{"term":"Politics"},{"term":"Examination"},{"term":"Intellectual Asset Management"},{"term":"Litigation"},{"term":"Patent litigation"},{"term":"Europe"},{"term":"Innovation patent"},{"term":"Patent attorney profession"},{"term":"Patents and society"},{"term":"Trolls"},{"term":"Claim construction"},{"term":"Licensing"},{"term":"Patentology admin"},{"term":"Economics"},{"term":"Novelty"},{"term":"Validity"},{"term":"Amendments"},{"term":"Legislation"},{"term":"Extension of patent term"},{"term":"Extensions of time"},{"term":"Opposition"},{"term":"Strategy"},{"term":"FRAND"},{"term":"International treaties"},{"term":"Evidence"},{"term":"Personal"},{"term":"Entitlement"},{"term":"Regulations"},{"term":"UK"},{"term":"Biotechnology"},{"term":"Compulsory license"},{"term":"Innovation"},{"term":"Public research"},{"term":"Federal Court practice"},{"term":"Government programs"},{"term":"Inventorship"},{"term":"Competition law"},{"term":"Designs"},{"term":"Google"},{"term":"Inventions"},{"term":"Official fees"},{"term":"PCT"},{"term":"Professional conduct"},{"term":"Reviews"},{"term":"Canada"},{"term":"Damages"},{"term":"History"},{"term":"Injunctions"},{"term":"Patent filing"},{"term":"Priority claim"},{"term":"WIPO"},{"term":"Accelerated examination"},{"term":"Amazon 1-click"},{"term":"Android"},{"term":"Divisional applications"},{"term":"Prior art"},{"term":"Statistics"},{"term":"Utility\/usefulness"},{"term":"Copyright"},{"term":"High Court"},{"term":"Indirect infringement"},{"term":"Oracle v Google"},{"term":"Patent pools"},{"term":"Scams"},{"term":"Backlog"},{"term":"Best method\/mode"},{"term":"False suggestion"},{"term":"Funding"},{"term":"Humour"},{"term":"Interference"},{"term":"Interview"},{"term":"Microsoft"},{"term":"Ownership"},{"term":"Provisional applications"},{"term":"Reexamination"},{"term":"Revocation"},{"term":"Book review"},{"term":"CCH"},{"term":"CRISPR"},{"term":"China"},{"term":"Confidential information"},{"term":"Conventions"},{"term":"Crown use"},{"term":"Enablement"},{"term":"Events"},{"term":"Fair Basis"},{"term":"Fatima Beattie"},{"term":"Fraud"},{"term":"Grace period"},{"term":"Intervening rights"},{"term":"Japan"},{"term":"Korea"},{"term":"Motorola"},{"term":"Open source"},{"term":"Patent analytics"},{"term":"Penalties for Infringement"},{"term":"Plant Breeder's Rights"},{"term":"Privileged communications"},{"term":"Register of Patents"},{"term":"Support"},{"term":"Technology standards"},{"term":"Trans-Pacific Partnership"},{"term":"Unjustified threats"},{"term":"Account of profits"},{"term":"Acquisitions"},{"term":"Apple"},{"term":"Broadband"},{"term":"Cloning"},{"term":"Constitution"},{"term":"Developing world"},{"term":"Double patenting"},{"term":"EU patent"},{"term":"Electronic communications"},{"term":"Employee inventions"},{"term":"Exhaustion"},{"term":"Experimental use defence"},{"term":"Extradition"},{"term":"Harmonisation"},{"term":"Inherency"},{"term":"Jurisdiction"},{"term":"Marking"},{"term":"Medical research"},{"term":"Omnibus claims"},{"term":"PPH"},{"term":"Paris Convention"},{"term":"Patent specifications"},{"term":"Publication"},{"term":"Samsung"},{"term":"Stay of proceedings"},{"term":"Tax incentives"},{"term":"Trademarks"},{"term":"Treaties"},{"term":"Unity"},{"term":"Valuation"},{"term":"Venice"},{"term":"AAT practice"},{"term":"ADR"},{"term":"Amicus curiae"},{"term":"Andrew Christie"},{"term":"Attorney fees"},{"term":"BSKB"},{"term":"Benjamin Mitra-Kahn"},{"term":"Commercialisation"},{"term":"Costs"},{"term":"Deadlines"},{"term":"Diagnostic methods"},{"term":"Discovery"},{"term":"Electronic Transactions Act 1999"},{"term":"Error correction"},{"term":"Estoppel"},{"term":"Evergreening"},{"term":"FOXTEL v TiVo"},{"term":"False marking"},{"term":"IPTA"},{"term":"In-house counsel"},{"term":"Indonesia"},{"term":"Insurance"},{"term":"Inventors"},{"term":"Joint infringement"},{"term":"Judicial review"},{"term":"Latin America"},{"term":"Maintenance fees"},{"term":"Media"},{"term":"Michael Cammarata"},{"term":"NPEs"},{"term":"Newsbytes"},{"term":"Non-disclosure agreements"},{"term":"Notice to Produce"},{"term":"Nullification of acceptance"},{"term":"Patent Cooperation Treaty"},{"term":"Patent drafting"},{"term":"Patent of addition"},{"term":"Peer-to-Patent"},{"term":"Philanthropy"},{"term":"Piracy"},{"term":"Prior use defence"},{"term":"Recipes"},{"term":"Regulatory use defence"},{"term":"Remedies"},{"term":"Science"},{"term":"Secret use"},{"term":"Security interests"},{"term":"Shark Tank"},{"term":"Soundbytes"},{"term":"Standard of proof"},{"term":"Stem Cells"},{"term":"Summary judgment"},{"term":"Surrender of patent"},{"term":"Survey"},{"term":"TRIPS"},{"term":"The Asian Century"},{"term":"USITC"},{"term":"Victoria"},{"term":"Vringo"},{"term":"Whole of contents"},{"term":"Yacht racing"},{"term":"ZTE"},{"term":"iOS"}],"title":{"type":"text","$t":"patentology"},"subtitle":{"type":"html","$t":""},"link":[{"rel":"http://schemas.google.com/g/2005#feed","type":"application/atom+xml","href":"http:\/\/blog.patentology.com.au\/feeds\/posts\/summary"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/summary?alt=json-in-script\u0026max-results=5\u0026category=Biotechnology,Biotechnology"},{"rel":"alternate","type":"text/html","href":"http:\/\/blog.patentology.com.au\/search\/label\/Biotechnology"},{"rel":"hub","href":"http://pubsubhubbub.appspot.com/"},{"rel":"next","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/summary?alt=json-in-script\u0026start-index=6\u0026max-results=5\u0026category=Biotechnology,Biotechnology"}],"author":[{"name":{"$t":"Mark Summerfield"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"32","height":"32","src":"\/\/lh4.googleusercontent.com\/-hzuCrd_SQBY\/AAAAAAAAAAI\/AAAAAAAAC14\/2R-Hb7Z8zys\/s512-c\/photo.jpg"}}],"generator":{"version":"7.00","uri":"http://www.blogger.com","$t":"Blogger"},"openSearch$totalResults":{"$t":"10"},"openSearch$startIndex":{"$t":"1"},"openSearch$itemsPerPage":{"$t":"5"},"entry":[{"id":{"$t":"tag:blogger.com,1999:blog-1574330275867774277.post-1235058031247277941"},"published":{"$t":"2016-08-21T15:51:00.000+10:00"},"updated":{"$t":"2016-08-21T15:51:23.289+10:00"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Australia"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Biotechnology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Diagnostic methods"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Litigation"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Patentable subject matter"},{"scheme":"http://www.blogger.com/atom/ns#","term":"US"}],"title":{"type":"text","$t":"After US Loss, Sequenom Takes Its Patent Battle With Ariosa Down-Under"},"summary":{"type":"text","$t":"One of the many benefits of genetic testing is the ability to carry out prenatal diagnosis of genetic disorders, most notably including (but certainly not limited to) Downs Syndrome.  This can be particularly valuable when one or both parents are known to be carriers of a genetic mutation such that the baby may be at significant risk of developing a serious condition or abnormality.  The "},"link":[{"rel":"replies","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/08\/after-us-loss-sequenom-takes-its-patent.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/1235058031247277941"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/1235058031247277941"},{"rel":"alternate","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/08\/after-us-loss-sequenom-takes-its-patent.html","title":"After US Loss, Sequenom Takes Its Patent Battle With Ariosa Down-Under"}],"author":[{"name":{"$t":"Mark Summerfield"},"uri":{"$t":"https:\/\/plus.google.com\/116299882295651429004"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"32","height":"32","src":"\/\/lh4.googleusercontent.com\/-hzuCrd_SQBY\/AAAAAAAAAAI\/AAAAAAAAC14\/2R-Hb7Z8zys\/s512-c\/photo.jpg"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/lh3.googleusercontent.com\/-Pu70Lq6Y-j8\/V7lAwkyeWeI\/AAAAAAAAD9A\/YoqTMGPoE_w\/s72-c\/Pregnant%25255B4%25255D.png?imgmax=800","height":"72","width":"72"},"thr$total":{"$t":"0"}},{"id":{"$t":"tag:blogger.com,1999:blog-1574330275867774277.post-6446331373798950248"},"published":{"$t":"2016-05-16T00:41:00.000+10:00"},"updated":{"$t":"2016-05-16T00:41:20.325+10:00"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Biotechnology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Computer programs"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Patentable subject matter"},{"scheme":"http://www.blogger.com/atom/ns#","term":"US"}],"title":{"type":"text","$t":"Patentable Subject Matter Continues to Confound in the US Despite Hopeful Signs"},"summary":{"type":"text","$t":"The past couple of weeks have brought some slightly brighter news for innovators in life sciences and software fields seeking patent protection in the United States.  First, the US Patent and Trademark Office (USPTO) issued an update to its Interim Guidance on Subject Matter Eligibility which provides some much needed clarification on what is expected from examiners, as well as additional "},"link":[{"rel":"replies","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/05\/patentable-subject-matter-continues-to.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/6446331373798950248"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/6446331373798950248"},{"rel":"alternate","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/05\/patentable-subject-matter-continues-to.html","title":"Patentable Subject Matter Continues to Confound in the US Despite Hopeful Signs"}],"author":[{"name":{"$t":"Mark Summerfield"},"uri":{"$t":"https:\/\/plus.google.com\/116299882295651429004"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"32","height":"32","src":"\/\/lh4.googleusercontent.com\/-hzuCrd_SQBY\/AAAAAAAAAAI\/AAAAAAAAC14\/2R-Hb7Z8zys\/s512-c\/photo.jpg"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/lh3.googleusercontent.com\/-iXq6AGA3KpM\/VziJNEcfEDI\/AAAAAAAAD3Q\/pvz6wP6x05o\/s72-c\/Hope%252520-%252520Despair%25255B4%25255D.png?imgmax=800","height":"72","width":"72"},"thr$total":{"$t":"0"}},{"id":{"$t":"tag:blogger.com,1999:blog-1574330275867774277.post-1524981252004196846"},"published":{"$t":"2016-04-17T16:49:00.000+10:00"},"updated":{"$t":"2016-04-17T16:49:36.946+10:00"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Biotechnology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Commercialisation"},{"scheme":"http://www.blogger.com/atom/ns#","term":"CRISPR"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Genetic technology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Interference"},{"scheme":"http://www.blogger.com/atom/ns#","term":"US"}],"title":{"type":"text","$t":"CRISPR Patent Dispute – Is It Just Too Big to Settle?"},"summary":{"type":"text","$t":"The proceedings at the US Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB), to determine who is entitled to foundational patent rights relating to CRISPR\/Cas9 ‘gene editing’ technology, have been steadily progressing since my last update back in January.  As a reminder, the parties vying for ownership of these rights are a group led by Berkeley Professor of Chemistry "},"link":[{"rel":"replies","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/04\/crispr-patent-dispute-is-it-just-too.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/1524981252004196846"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/1524981252004196846"},{"rel":"alternate","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/04\/crispr-patent-dispute-is-it-just-too.html","title":"CRISPR Patent Dispute – Is It Just Too Big to Settle?"}],"author":[{"name":{"$t":"Mark Summerfield"},"uri":{"$t":"https:\/\/plus.google.com\/116299882295651429004"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"32","height":"32","src":"\/\/lh4.googleusercontent.com\/-hzuCrd_SQBY\/AAAAAAAAAAI\/AAAAAAAAC14\/2R-Hb7Z8zys\/s512-c\/photo.jpg"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/lh3.googleusercontent.com\/-aoHn_g8oLZM\/VxMwo9nR81I\/AAAAAAAAD0w\/xu_5H7Se83w\/s72-c\/Big%252520money%25255B4%25255D.png?imgmax=800","height":"72","width":"72"},"thr$total":{"$t":"0"}},{"id":{"$t":"tag:blogger.com,1999:blog-1574330275867774277.post-1138737173352625243"},"published":{"$t":"2016-01-31T12:38:00.003+11:00"},"updated":{"$t":"2016-01-31T12:38:29.589+11:00"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Biotechnology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"CRISPR"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Genetic technology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Interference"},{"scheme":"http://www.blogger.com/atom/ns#","term":"US"}],"title":{"type":"text","$t":"CRISPR Interference Update"},"summary":{"type":"text","$t":"Two weeks ago I wrote about the interference proceedings that have been instituted by the US Patent and Trademarks Office (USPTO) in order to determine who is rightfully entitled to fundamental patent rights in relation to CRISPR gene-editing technology, under the former ‘first-to-invent’ priority rules.  The contest is between a team led by Berkeley Professor of Chemistry Jennifer Doudna and her"},"link":[{"rel":"replies","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/01\/crispr-interference-update.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/1138737173352625243"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/1138737173352625243"},{"rel":"alternate","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/01\/crispr-interference-update.html","title":"CRISPR Interference Update"}],"author":[{"name":{"$t":"Mark Summerfield"},"uri":{"$t":"https:\/\/plus.google.com\/116299882295651429004"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"32","height":"32","src":"\/\/lh4.googleusercontent.com\/-hzuCrd_SQBY\/AAAAAAAAAAI\/AAAAAAAAC14\/2R-Hb7Z8zys\/s512-c\/photo.jpg"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/lh3.googleusercontent.com\/-94dDRdaUhIY\/Vq1kJWeqKCI\/AAAAAAAADvM\/_Q-y9P5AqVI\/s72-c\/DNA%25255B4%25255D.png?imgmax=800","height":"72","width":"72"},"thr$total":{"$t":"0"}},{"id":{"$t":"tag:blogger.com,1999:blog-1574330275867774277.post-7157227465087657008"},"published":{"$t":"2016-01-17T16:33:00.000+11:00"},"updated":{"$t":"2016-01-17T16:33:21.981+11:00"},"category":[{"scheme":"http://www.blogger.com/atom/ns#","term":"Biotechnology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"CRISPR"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Genetic technology"},{"scheme":"http://www.blogger.com/atom/ns#","term":"Interference"},{"scheme":"http://www.blogger.com/atom/ns#","term":"US"}],"title":{"type":"text","$t":"Who Will Get the CRISPR Patent?"},"summary":{"type":"text","$t":"As has been widely reported, the US Patent and Trademark Office (USPTO) has instituted interference proceedings to determine who is entitled to own foundational patent rights in relation to CRISPR\/Cas9 ‘gene editing’ technology.  I wrote about this brewing dispute back in July 2015, when I predicted that this would be ‘the last great US patent interference’, given that the US patent system "},"link":[{"rel":"replies","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/01\/who-will-get-crispr-patent.html#comment-form","title":"0 Comments"},{"rel":"edit","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/7157227465087657008"},{"rel":"self","type":"application/atom+xml","href":"http:\/\/www.blogger.com\/feeds\/1574330275867774277\/posts\/default\/7157227465087657008"},{"rel":"alternate","type":"text/html","href":"http:\/\/blog.patentology.com.au\/2016\/01\/who-will-get-crispr-patent.html","title":"Who Will Get the CRISPR Patent?"}],"author":[{"name":{"$t":"Mark Summerfield"},"uri":{"$t":"https:\/\/plus.google.com\/116299882295651429004"},"email":{"$t":"noreply@blogger.com"},"gd$image":{"rel":"http://schemas.google.com/g/2005#thumbnail","width":"32","height":"32","src":"\/\/lh4.googleusercontent.com\/-hzuCrd_SQBY\/AAAAAAAAAAI\/AAAAAAAAC14\/2R-Hb7Z8zys\/s512-c\/photo.jpg"}}],"media$thumbnail":{"xmlns$media":"http://search.yahoo.com/mrss/","url":"https:\/\/lh3.googleusercontent.com\/-nvQNlpmxyLM\/VpsmrHHYUMI\/AAAAAAAADuY\/ckKG6SPRU7Y\/s72-c\/Crispy%25255B5%25255D.png?imgmax=800","height":"72","width":"72"},"thr$total":{"$t":"0"}}]}});